Workflow
燃石医学上涨7.54%,报7.517美元/股,总市值8093.25万美元

Core Insights - The stock price of Burning Stone Medical (BNR) increased by 7.54% on August 14, reaching $7.517 per share, with a total market capitalization of $80.93 million [1] - As of March 31, 2025, the total revenue of Burning Stone Medical was 133 million RMB, reflecting a year-on-year growth of 5.94%, while the net profit attributable to the parent company was -13.5 million RMB, showing a significant year-on-year increase of 88.89% [1] Company Overview - Burning Stone Medical, established in 2014, focuses on providing clinically valuable next-generation sequencing (NGS) for precision oncology, with a mission to "guard the light of life with science" [2] - The company's business and R&D directions include: 1) detection of cancer patient populations, holding a leading market share in China; 2) collaboration with global anti-cancer pharmaceutical companies on biomarkers and companion diagnostics; 3) early detection of multiple cancer types [2] - The company received the first NGS testing kit certification for tumors from the National Medical Products Administration (NMPA) in July 2018, marking a milestone in the in vitro diagnostic field [2] - The laboratory in Guangzhou, China, has passed the technical review by the Guangdong Provincial Clinical Testing Center and obtained quality system certifications from CLIA and CAP, while the laboratory in California, USA, has also received CLIA and CAP certifications [2] - Burning Stone Medical is committed to developing innovative and reliable NGS testing products to advance the field of precision oncology [2]